ARCHIVES

Carfilzomib Demonstrates Clinical Benefit Rate of 64%

This article is from The Cancer Letter archive.

Vol. 34 No. 12 | December 30, 2011

Download PDF Visit The Full Archive

Related Articles

Study Finds Physician Referral By Centers Fraught With Problems, Potential Dangers

July 23, 1976

Human Subject Rules Now Have forces Of Law; Already Conforming

June 7, 1974

Phase III Trial of Avastin and Temozolomide Shows Reduced Risk of Cancer Progression

November 30, 2012

Wisconsin Funds State Cancer Control Program

July 15, 1988

NIH Carcinogen Guidelines Offered

April 24, 1981

Sen. Edward Kennedy Receives ACS Medal

January 23, 2009